Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration in January 2014, for the treatment of non-24-hour sleep-wake disorder. It is a synthetic small-molecule agonist at melatonin receptors MT1 and MT2 that targets the suprachiasmatic nucleus to entrain circadian timing. Administered orally as a 20 mg once-daily tablet at bedtime, tasimelteon is formulated as a film-coated solid dosage form and is subject to first-pass hepatic metabolism primarily via cytochrome P450 isoenzymes with inactive metabolites excreted in urine. Clinical effect is described as phase-shifting and consolidation of sleep timing rather than traditional hypnotic sedation, and safety monitoring includes assessment of hepatic function and potential drug interactions with strong CYP modulators.
Typical commercial and regulatory quality control limits for tasimelteon drug substance and finished product specify a high-purity profile with assay acceptance commonly 98.0 percent or greater. Known related compounds arising from synthetic routes and degradation pathways include small amounts of dealkylation products, oxidative byproducts, hydrolytic fragments and potential stereoisomeric impurities; individual identified related compounds are commonly controlled in the range of 0.2 to 0.5 percent each, with total impurities routinely limited to approximately 1.5 percent or less. Residual solvents are controlled to ICH Q3C class limits and elemental impurities are controlled per ICH Q3D. Specifications and impurity limits may vary by manufacturer and regulatory filing, and impurity identification is typically confirmed by validated HPLC, MS and NMR methods.
Tasimelteon is indicated for the treatment of non-24-hour sleep-wake disorder, a circadian rhythm disorder most commonly seen in totally blind individuals who lack light perception. It is used to entrain the internal circadian pacemaker to a 24-hour day to improve sleep timing and daytime functioning.
No. Tasimelteon is a synthetic selective agonist of melatonin receptor subtypes MT1 and MT2 and is a regulated prescription medication with defined pharmacokinetics and dosing. Melatonin is an endogenous hormone and over-the-counter melatonin supplements vary in purity, dose and receptor activity. Tasimelteon is designed, tested and approved as a pharmaceutical agent for circadian entrainment.
Price factors include the cost of drug discovery and clinical development for a narrowly indicated orphan-type circadian disorder, manufacturing and quality control for a high-purity active pharmaceutical ingredient, requirements for long-term stability and regulatory compliance, and limited patient population and market volume that reduce economies of scale.
Tasimelteon acts as an agonist at melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus, the brain region that governs circadian rhythms. Activation of these receptors advances or stabilizes the timing of the circadian pacemaker, promoting entrainment to the 24-hour day and thereby improving the timing of sleep and wakefulness rather than producing direct hypnotic sedation.
